Article
press release
Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute will join with colleagues this week to share the latest advances in oncology pharmacy operations and dispensing practices at the NCODA 2023 Spring Forum in Indianapolis.
Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute (FCS) will join with colleagues this week to share the latest advances in oncology pharmacy operations and dispensing practices at the NCODA 2023 Spring Forum in Indianapolis. Titled, Transforming Patient Care in a Diverse Oncology Landscape, the multi-day gathering of global oncology professionals will focus on advances in patient care through improvements in pharmacy operations.
The medically integrated oncology pharmacy for FCS, Rx To Go, located in a 20,000 square foot, state-of-the-art facility in Ft. Myers, Florida, works exclusively with the statewide practice’s physicians, clinicians and patients to provide timely dispensing and convenient home delivery of oral oncolytic medications.
“More than 35 percent of the drugs used in cancer treatment today are administered orally,” said FCS President & Managing Physician Lucio Gordan, MD. “Our Rx To Go team members provide an advanced level of personalized pharmacy and support services to ensure that patients use medications appropriately and achieve optimal clinical outcomes.”
Serving as presenters and panelists during interactive workshops and discussions at the NCODA Spring Forum are:
“Our pharmacy professionals have much to contribute toward efforts that will enhance the value of medically integrated pharmacies for patients and providers,” said FCS Chief Executive Officer Nathan H. Walcker. “Their demonstrated commitment to best-in-class standards for practice management, patient care and quality improvement has resulted in industry recognition and consecutive prestigious accreditations.”
NCODA is a globally recognized not-for-profit organization dedicated to building a patient-centered, medically integrated community of health care providers whose focus is to innovate the continuity of cancer care so that every patient receives the maximum benefit from their cancer treatment.
In addition to participation and attendance of the 2023 NCODA Spring Forum, several FCS Executive and Senior Management Leaders, Pharmacy Operations, and Rx To Go team members serve on NCODA committees. Later this year, the statewide practice will also welcome its first resident through NCODA’s Accredited Medically-Integrated Oncology Pharmacy (MIP) Residency Program, a one-year training program designed specifically for students interested in an oncology pharmacy career path.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
2 Commerce Drive
Cranbury, NJ 08512